Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Director | June 16, 2026 | June 17, 2026 |
| Korsana Biosciences, Inc.CYCN · Entity 7698 | President and CSO | December 28, 2020 | December 30, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRONWOOD PHARMACEUTICALS INC
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 676,900 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 63,481 · Balance 676,900 F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock, granted pursuant to the Second Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2024, vests in full on the date immediately preceding the date of the annual meeting of stockholders for the next calendar year.
Korsana Biosciences, Inc.
Report date December 28, 2020 · Filed December 30, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 251,648 |
Reported balance
After 2020-12-28 transaction · row 1
1 source rowRow 1 · 2020-12-28 · Sale · Disposed 20,107 · Balance 251,648 F1: The proceeds from the sale are intended to cover income taxes arising out of prior stock option exercises, including those in which the reporting person held the underlying shares. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.94 to $3.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The proceeds from the sale are intended to cover income taxes arising out of prior stock option exercises, including those in which the reporting person held the underlying shares.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.94 to $3.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 22, 2018 Filed Aug 24, 2018 21:21 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass B Common Stock | 65,000 | $18.51 | $1,203,150.00 |
DisclosureSEC source: 0001209191-18-048410 · doc4.xml · nonDerivative · entry 4 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. In order to effect the sale, these shares of Class B Common Stock were converted into shares of Class A Common Stock in accordance with the issuer's certificate of incorporation. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.18 to $18.66, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 22, 2018 Filed Aug 24, 2018 21:21 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 6,667 | $5.48 | $36,535.16 |
DisclosureSEC source: 0001209191-18-048410 · doc4.xml · nonDerivative · entry 3 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 840,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2018 Filed Aug 24, 2018 21:21 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 41,667 | $4.89 | $203,751.63 |
DisclosureSEC source: 0001209191-18-048410 · doc4.xml · nonDerivative · entry 2 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 833,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2018 Filed Aug 24, 2018 21:21 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 16,666 | $4.89 | $81,496.74 |
DisclosureSEC source: 0001209191-18-048410 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 791,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 22:01 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-045056 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,124 F1 · kind: The restricted stock unit award, granted as a recognition award, vests as to 100% of the shares of Class A Common Stock on May 9, 2019. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 23:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option(Right to Buy) · Derivative | 215,000 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-18-012585 · doc4.xml · derivative · entry 3 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Class A Common Stock · 215,000 shares Expires 2028-02-21 F3 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2018. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 23:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,634 | $14.66 | $23,954.44 |
DisclosureSEC source: 0001209191-18-012585 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,124 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.48 to $14.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:09 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001209191-18-005550 · doc4.xml · derivative · entry 4 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 60,000 shares Expires 2018-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2008 for the first 36 months, and as to 4.5833% of the shares of Class B Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2012. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:09 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass B Common Stock | 60,000 | $15.45 | $927,000.00 |
DisclosureSEC source: 0001209191-18-005550 · doc4.xml · nonDerivative · entry 2 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,000 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. In order to effect the sale, these shares of Class B Common Stock were converted into shares of Class A Common Stock in accordance with the issuer's certificate of incorporation. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.10 to $15.92, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:09 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 60,000 | $3.76 | $225,600.00 |
DisclosureSEC source: 0001209191-18-005550 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 835,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2017 Filed Dec 11, 2017 23:01 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GiftClass A Common Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-065071 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,758 Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 21:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $3.76 Strike: $3.76 | $225,600.00 |
DisclosureSEC source: 0001209191-17-021128 · doc4.xml · derivative · entry 4 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Class B Common Stock · 60,000 shares Expires 2018-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2008 for the first 36 months, and 4.5833% of the shares of Class B Common Stock vested on each monthly anniversary thereafter for the next 12 months. This option was fully vested as of January 1, 2012. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 21:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass B Common Stock | 60,000 | $17.06 | $1,023,600.00 |
DisclosureSEC source: 0001209191-17-021128 · doc4.xml · nonDerivative · entry 2 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,000 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.99 to $17.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 21:08 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 60,000 | $3.76 | $225,600.00 |
DisclosureSEC source: 0001209191-17-021128 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 835,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 23:26 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $16.77 | $0.00 |
DisclosureSEC source: 0001209191-17-016104 · doc4.xml · derivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Class A Common Stock · 250,000 shares Expires 2027-02-27 F1 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2017. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:38 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,800 | $16.94 | $30,492.00 |
DisclosureSEC source: 0001209191-17-014374 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,258 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.47 to $17.41, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 22:57 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 55,987 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001209191-17-004975 · doc4.xml · derivative · entry 3 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 55,987 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2007 for the first 36 months, and as to 4.5833% of the shares of Class B Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2011. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 22:57 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 55,987 | $2.94 | $164,601.78 |
DisclosureSEC source: 0001209191-17-004975 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2017 Filed Jan 10, 2017 22:31 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 34,013 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001209191-17-003240 · doc4.xml · derivative · entry 3 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,987 Underlying: Class B Common Stock · 34,013 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2007 for the first 36 months, and as to 4.5833% of the shares of Class B Common Stock each monthly anniversary thereafter. The option was fully vested as of January 1, 2011. Read SEC document |
| January 06, 2017 Filed Jan 10, 2017 22:31 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 34,013 | $2.94 | $99,998.22 |
DisclosureSEC source: 0001209191-17-003240 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 719,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2016 Filed Dec 8, 2016 22:04 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GiftClass A Common Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-154198 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,058 Read SEC document |
| October 31, 2016 Filed Nov 1, 2016 22:16 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $2.94 | $0.00 |
DisclosureSEC source: 0001209191-16-147712 · doc4.xml · derivative · entry 3 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 300,000 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On October 31, 2016, the reporting person exercised the option pursuant to an early exercise provision. The right to acquire the shares will vest upon the earlier of (i) the Issuer's achievement of certain clinical, regulatory and market capitalization milestones and (ii) January 22, 2017. Read SEC document |
| October 31, 2016 Filed Nov 1, 2016 22:16 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 300,000 | $2.94 | $882,000.00 |
DisclosureSEC source: 0001209191-16-147712 · doc4.xml · nonDerivative · entry 1 Currie Mark G · CIK 0001478244 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 685,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The right to acquire the shares will vest upon the earlier of (i) the Issuer's achievement of certain clinical, regulatory and market capitalization milestones and (ii) January 22, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.